Trial Profile
An Open-label Multicentre, Follow-up Trial to Assess the Long-term Safety and Tolerability of Oral Administration of Talsaclidine 24 mg Tid in Patients With Mild to Moderate Dementia of the Alzheimer Type
Status:
Discontinued
Phase of Trial:
Phase II/III
Latest Information Update: 06 Oct 2014
Price :
$35
*
At a glance
- Drugs Talsaclidine (Primary)
- Indications Alzheimer's disease; Dementia
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 06 Oct 2014 New trial record